CD274 and adenocarcinoma: In the progression of immunotherapy in adenocarcinomas of the stomach/gastroesophageal junction, it remains necessary to further identify and subdivide subgroups and sex-specific differences of patients who particularly seem to benefit from response to immunotherapy by possible predictive biomarkers (PD-L1 CPS, MSI, EBV) within the upcoming years.